While an AR:ER positivity ratio of 78% has been demonstrated to have the prognostic capacity in AR+/ER+ tumours [48], a more complete understanding of how signaling of androgen and estrogen receptors, along with signaling of other receptors and growth factors, is influencing the radiation response is needed to effectively identify reliable biomarkers of response. This evidence concerns the gene ESR1 and neoplasm.